Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts.

VAN Noord RA, Thomas T, Krook M, Chukkapalli S, Hoenerhoff MJ, Dillman JR, Lawlor ER, Opipari VP, Newman EA.

In Vivo. 2017 Sep-Oct;31(5):779-791.

2.

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts.

Thomas TT, Chukkapalli S, Van Noord RA, Krook M, Hoenerhoff MJ, Dillman JR, Lawlor ER, Opipari VP, Newman EA.

J Vis Exp. 2018 May 25;(135). doi: 10.3791/57558.

PMID:
29889191
3.

Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis.

Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ.

In Vivo. 2002 Mar-Apr;16(2):77-85.

PMID:
12073775
4.

In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts.

Joseph JM, Gross N, Lassau N, Rouffiac V, Opolon P, Laudani L, Auderset K, Geay JF, M├╝hlethaler-Mottet A, Vassal G.

Int J Cancer. 2005 Mar 1;113(6):881-90.

5.

Establishment and characterization of new orthotopic and metastatic neuroblastoma models.

Daudigeos-Dubus E, LE Dret L, Rouffiac V, Bawa O, Leguerney I, Opolon P, Vassal G, Geoerger B.

In Vivo. 2014 Jul-Aug;28(4):425-34.

PMID:
24982206
6.

Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice.

Sartelet H, Durrieu L, Fontaine F, Nyalendo C, Haddad E.

In Vivo. 2012 Jan-Feb;26(1):19-29.

PMID:
22210712
7.

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.

Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP.

Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.

8.

Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.

Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Redini F.

BMC Cancer. 2014 Mar 10;14:169. doi: 10.1186/1471-2407-14-169.

9.

Establishment of a neuroblastoma mouse model by subcutaneous xenograft transplantation and its use to study metastatic neuroblastoma.

Gao Q, Chen CF, Dong Q, Hou L, Chen X, Zhi YL, Li X, Lu HT, Zhang HY.

Genet Mol Res. 2015 Dec 8;14(4):16297-307. doi: 10.4238/2015.December.8.20.

10.

Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.

Murakami T, Li S, Han Q, Tan Y, Kiyuna T, Igarashi K, Kawaguchi K, Hwang HK, Miyake K, Singh AS, Nelson SD, Dry SM, Li Y, Hiroshima Y, Lwin TM, DeLong JC, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM.

Oncotarget. 2017 May 30;8(22):35630-35638. doi: 10.18632/oncotarget.15823.

11.

Generation and characterization of novel local and metastatic human neuroblastoma variants.

Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva L, Schwab M, Yron I, Witz IP.

Neoplasia. 2008 Aug;10(8):816-27.

12.

Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.

Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, Sharma A, Blair H, Hide IG, Heidenreich O, Vormoor J, Maxwell RJ, Bacon CM.

PLoS One. 2014 Jan 7;9(1):e85128. doi: 10.1371/journal.pone.0085128. eCollection 2014.

13.

High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.

Hong SH, Tilan JU, Galli S, Izycka-Swieszewska E, Polk T, Horton M, Mahajan A, Christian D, Jenkins S, Acree R, Connors K, Ledo P, Lu C, Lee YC, Rodriguez O, Toretsky JA, Albanese C, Kitlinska J.

Oncotarget. 2015 Mar 30;6(9):7151-65.

14.

Analyses of Tumor Burden In Vivo and Metastasis Ex Vivo Using Luciferase-Expressing Cancer Cells in an Orthotopic Mouse Model of Neuroblastoma.

Byrne FL, McCarroll JA, Kavallaris M.

Methods Mol Biol. 2016;1372:61-77. doi: 10.1007/978-1-4939-3148-4_5.

PMID:
26530915
15.

Preclinical models for neuroblastoma: establishing a baseline for treatment.

Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, Zhang J, Johnson MD, Sedlacik J, Inoue M, Zhang ZM, Frase S, Rehg JE, Hillenbrand CM, Finkelstein D, Calabrese C, Dyer MA, Lahti JM.

PLoS One. 2011 Apr 29;6(4):e19133. doi: 10.1371/journal.pone.0019133.

16.
17.

Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence.

Pagani A, Fischer-Colbrie R, Eder U, Pellin A, Llombart-Bosch A, Bussolati G.

Int J Cancer. 1995 Nov 27;63(5):738-43.

PMID:
7591294
18.

Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study.

Guo J, Cai J, Zhang Y, Zhu Y, Yang P, Wang Z.

Int J Oncol. 2017 Oct;51(4):1199-1208. doi: 10.3892/ijo.2017.4115. Epub 2017 Sep 4.

PMID:
28902355
19.

In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines.

Timeus F, Crescenzio N, Fandi A, Doria A, Foglia L, Cordero di Montezemolo L.

Oncol Rep. 2008 Feb;19(2):353-9.

PMID:
18202781
20.

Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.

Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES.

Mol Cancer Ther. 2008 Jul;7(7):1807-16. doi: 10.1158/1535-7163.MCT-08-0058.

Supplemental Content

Support Center